184 related articles for article (PubMed ID: 20422410)
1. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide.
Berge G; Eliassen LT; Camilio KA; Bartnes K; Sveinbjørnsson B; Rekdal O
Cancer Immunol Immunother; 2010 Aug; 59(8):1285-94. PubMed ID: 20422410
[TBL] [Abstract][Full Text] [Related]
2. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315.
Camilio KA; Berge G; Ravuri CS; Rekdal O; Sveinbjørnsson B
Cancer Immunol Immunother; 2014 Jun; 63(6):601-13. PubMed ID: 24676901
[TBL] [Abstract][Full Text] [Related]
3. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.
Chung Y; Qin H; Kang CY; Kim S; Kwak LW; Dong C
Blood; 2007 Sep; 110(6):2013-9. PubMed ID: 17581919
[TBL] [Abstract][Full Text] [Related]
4. Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts.
Furlong SJ; Mader JS; Hoskin DW
Exp Mol Pathol; 2010 Jun; 88(3):371-5. PubMed ID: 20171209
[TBL] [Abstract][Full Text] [Related]
5. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma.
Meziane el K; Bhattacharyya T; Armstrong AC; Qian C; Hawkins RE; Stern PL; Dermime S
Int J Cancer; 2004 Oct; 111(6):910-20. PubMed ID: 15300803
[TBL] [Abstract][Full Text] [Related]
6. Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma.
Heier I; Hofgaard PO; Brandtzaeg P; Jahnsen FL; Karlsson M
Clin Exp Immunol; 2008 May; 152(2):381-7. PubMed ID: 18341610
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect.
Hu G; Liu Y; Li H; Zhao D; Yang L; Shen J; Hong X; Cao X; Wang Q
Cell Mol Immunol; 2010 Jul; 7(4):296-305. PubMed ID: 20418899
[TBL] [Abstract][Full Text] [Related]
8. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effector functions of T cells are dependent on in vivo priming and restricted T-cell receptor expression.
Lüking C; Kronenberger K; Frankenberger B; Nössner E; Röcken M; Mocikat R
Int J Cancer; 2008 May; 122(10):2280-5. PubMed ID: 18224683
[TBL] [Abstract][Full Text] [Related]
11. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
12. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
Houot R; Levy R
Blood; 2009 Apr; 113(15):3546-52. PubMed ID: 18941113
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
Song W; Levy R
Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
[TBL] [Abstract][Full Text] [Related]
14. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
Briones J; Timmerman JM; Panicalli DL; Levy R
J Natl Cancer Inst; 2003 Apr; 95(7):548-55. PubMed ID: 12671023
[TBL] [Abstract][Full Text] [Related]
15. Generation of a hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin.
Hilchie AL; Vale R; Zemlak TS; Hoskin DW
Exp Mol Pathol; 2013 Oct; 95(2):192-8. PubMed ID: 23892223
[TBL] [Abstract][Full Text] [Related]
16. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
Siegel S; Wagner A; Schmitz N; Zeis M
Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
[TBL] [Abstract][Full Text] [Related]
18. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.
Brody JD; Goldstein MJ; Czerwinski DK; Levy R
Blood; 2009 Jan; 113(1):85-94. PubMed ID: 18812472
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
